Rapidemic
Financiado
Rapidemic – A lysis buffer for a novel molecular point-of-care diagnostic device...
Rapidemic – A lysis buffer for a novel molecular point-of-care diagnostic device for sexually transmitted infections
Sexually transmitted infections (STI) are some of the most prevalent endemic infections in Europe. Current diagnostic techniques for STI’s have important shortcomings, as they rely on central diagnostic laboratories with extensive...
Sexually transmitted infections (STI) are some of the most prevalent endemic infections in Europe. Current diagnostic techniques for STI’s have important shortcomings, as they rely on central diagnostic laboratories with extensive high-throughput facilities with expensive equipment and trained personnel. Due to this, the turnover of patient samples can take up to a week. In the meantime, patients are experiencing shame and pain. This delay in diagnosis can also have more important consequences, such as continued spread of the infections, of the development of pelvic inflammatory disease, which can lead to infertility.
This is why Rapidemic develops an innovative molecular point-of-care diagnostic device for fast and accurate diagnosis of chlamydia and gonorroea. With this test, patient samples no longer have to travel to a lab, but patients can immediately get tested at a sexual health clinic. This single-visit testing provides an opportunity for immediate treatment administration and to drastically reduce the patients discomfort, therby decreasing the barrier to test.
To detect a pathogen’s DNA in the Rapidemic test, the bacteria first have to release the DNA. In this project, Rapidemic will be working on the research and development of a novel lysis buffer for gram negative bacteria, suitable for integration in a molecular point-of-care diagnostic device.
ver más
Duración del proyecto: 6 meses
Fecha Inicio: 2023-06-02
Fecha Fin: 2023-12-31
Fecha Fin: 2023-12-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-12-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIE-2022-SCALEUP-02-02:
Women TechEU
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
75K€
Líder del proyecto
RAPIDEMIC B.V.
No se ha especificado una descripción o un objeto social para esta compañía.
